A series of studies in the early 2000s observed that distinct epidemiological subgroups of patients with NSCLC had dramatically enhanced responses to treatment with the ATP-competitive, reversible EGFR inhibitors gefitinib and erlotinib.48 Meanwhile, EGFR inhibitors as angiogenesis inhibitors are significantly associated with an increased risk of arterial thromboembolism.49 Less than 10% of NSCLC patients have an objective tumor response. This evidence concerns the gene EGFR and neoplasm.